RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Hb S/beta-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort
Clinical, laboratory and molecular characteristics
Belisário, A. R., Carneiro-Proietti, A. B., Sabino, E. C., Araújo, A., Loureiro, P., Máximo, C., Flor-Park, M. V., Rodrigues, D. D. O. W., Ozahata, M. C., McClure, C., Mota, R. A., Gomes Moura, I. C., Custer, B., Kelly, S., & Recipient Epidemiology and Donor Evaluation Study (REDS-III) International Component Brazil (2020). Hb S/beta-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort: Clinical, laboratory and molecular characteristics. Hemoglobin, 44(1), 1-9. https://doi.org/10.1080/03630269.2020.1731530
We described the clinical, laboratory and molecular characteristics of individuals with Hb S (HBB: c.20A>T)/beta-thalassemia (Hb S/beta-thal) participating in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) Brazil Sickle Cell Disease cohort. HBB gene sequencing was performed to genotype each beta-thal mutation. Patients were classified as Hb S/beta(0)-thal, Hb S/beta(+)-thal-severe or Hb S/beta(+)-thal based on prior literature and databases of hemoglobin (Hb) variants. Characteristics of patients with each beta-thal mutation were described and the clinical profile of patients grouped into Hb S/beta(0)-thal, Hb S/beta(+)-thal and Hb S/beta(+)-thal-severe were compared. Of the 2793 patients enrolled, 84 (3.0%) had Hb S/beta(0)-thal and 83 (3.0%) had Hb S/beta(+)-thal; 40/83 (48.2%) patients with Hb S/beta(+)-thal had mutations defined as severe. We identified 19 different beta-thal mutations, eight Hb S/beta(0)-thal, three Hb S/beta(+)-thal-severe and eight Hb S/beta(+)-thal. The most frequent beta(0) and beta(+) mutations were codon 39 (HBB: c.118C>T) and IVS-I-6 (T>C) (HBB: c.92+6T>C), respectively. Individuals with Hb S/beta(0)-thal had a similar clinical and laboratory phenotype when compared to those with Hb S/beta(+)-thal-severe. Individuals with Hb S/beta(+)-thal-severe had significantly lower total Hb and Hb A levels and higher Hb S, white blood cell (WBC) count, platelets and hemolysis markers when compared to those with Hb S/beta(+)-thal. Likewise, individuals with Hb S/beta(+)-thal-severe showed a significantly higher occurrence of hospitalizations, vaso-occlusive events (VOE), acute chest syndrome (ACS), splenic sequestration, blood utilization, and hydroxyurea (HU) therapy.